Ocuphire Pharma Investor Presentation Deck

Landscape of Invasive Therapies (IVT/Suprachoroidal) for Diabetic Retinopathy EyleaⓇ/Lucentis® Approved, But Not Used in Patients with NPDR; Rarely Used in Mild PDR Company REGENERON Roche KODIAK EYEPOINT PHARMACEUTICALS Boehringer Ingelheim Therapeutix REGENXBIO® Drug Eylea (aflibercept) Lucentis® (ranibizumab) KSI-301 (Tarcocimab) EYP-1901 BI 764524 OTX-TKI RGX-314 Target/MOA VEGF-A/B; PIGF VEGF-A VEGF Voloronib* (TKI) Anti-Sema3A Ischemia modulator Axitinib* (TKI) AAV8-VEGF Ocuphire Company websites and www.clinical trials.gov (as of July 31, 2023) Route of Administration Eylea® is trademark of Regeneron and Lucentis® is trademark of Genentech Intravitreal Intravitreal Intravitreal Intravitreal Intravitreal Intravitreal * Failed as oral/systemic treatments in retina due to dose limiting toxicity Suprachoroidal (Gene Therapy) Phase 1 ✓ ✓ Phase 2 ✓ N/A Completed Phase 3 Commercial ✓*1 ✓*2 Ongoing X Discontinued *Trials to Support Approval 1 Panorama Clinical Trial 2 Protocol I & T and Rise & Ride 13

View entire presentation